248 related articles for article (PubMed ID: 21446886)
1. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
3. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
[TBL] [Abstract][Full Text] [Related]
4. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
6. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
7. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
van der Meel R; Oliveira S; Altintas I; Heukers R; Pieters EH; van Bergen en Henegouwen PM; Storm G; Hennink WE; Kok RJ; Schiffelers RM
Mol Pharm; 2013 Oct; 10(10):3717-27. PubMed ID: 23889133
[TBL] [Abstract][Full Text] [Related]
9. Targeting IGF-1 signaling pathways in gynecologic malignancies.
Bruchim I; Werner H
Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
[TBL] [Abstract][Full Text] [Related]
10. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
12. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
Wood ER; Shewchuk L; Hassel A; Nichols J; Truesdale AT; Smith D; Carter HL; Weaver K; Barrett G; Leesnitzer T; Alvarez E; Bardera AI; Alamillo A; Cantizani J; Martin J; Smith GK; Jensen DE; Xie H; Mook R; Kumar R; Kuntz K
Biochem Pharmacol; 2009 Dec; 78(12):1438-47. PubMed ID: 19665448
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
15. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
16. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
18. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
19. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
Mitsiades CS; Mitsiades N
Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]